Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by 1998novlon May 03, 2020 8:15pm
169 Views
Post# 30981881

RE:RE:RE:RE:RE:New Corp presentation posted

RE:RE:RE:RE:RE:New Corp presentation postedThanks JFM, miss having you around as a shareholder but that's what makes a market! My take is the new CEO brings with him a vast network of contacts and credibility - who can influence change through his network. It doesn't take much, and in fact being around doctors (as my wife is one) - they are not all the same in their ways. The old cohort is retiring and the new docs are open to changing - so I am an optimist - mind you I own close to 200,000 shares personally so call me biased!  The company is now set up for the long term, and that is important to me. I see a path to profitability and a pipeline to grow revenues. In a world where the markets will be all over the place, I think paying between 2-3 times 2020 sales now for a company that will likely have over 300M in sales in 2025, is a pretty reasonable investment, as I think multiple expansion is very plausible during the next 5 years. The math looks good to me. But time will tell, and that's what investing is all about. GLTA
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse